Ahead of the launch, the firm has taken steps to amplify its production capacities to ensure adequate supply, and believes ...

COPENHAGEN (Reuters) -Drugmaker Novo Nordisk said on Monday it would halt its Wegovy weight-loss drug agreement with U.S.

Novo Nordisk’s new weight-loss drug helped patients lose even more weight on average than its current Wegovy blockbuster ...

Novo Nordisk's U.S.-listed shares fell more than 5% Monday after the drugmaker revealed the latest results for a new ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for patients who have a prescription for the medication but no insurance coverage ...

Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing ...

Novo Nordisk ended its agreement with Hims & Hers for the sale of Wegovy after disagreements over marketing tactics and ...

Novo Nordisk said on Monday it would halt its collaboration with Hims & Hers Health over the sale of weight loss drugs. The ...

Novo Nordisk has ended its collaboration with Hims & Hers Health for its Wegovy weight-loss blockbuster treatment roughly a month after it began over concerns about what it said was illegal mass ...

Novo Nordisk unveiled its latest data for a weight-loss drug candidate, but shares of the maker of Wegovy and Ozempic tumbled ...

Novo Nordisk said in a statement on Monday that direct access to Wegovy would no longer be available to Hims & Hers Health ...